In 2019, Jeni Doerr finally received a diagnosis for her recent illnesses – pancolitis. Doerr, 35, from Newhall, CA, is featured in AAM’s recently released 2020 Generic Drug & Biosimilars Access & Savings in the U.S. report.
Here’s Jeni’s story, in her own words:
“I had been experiencing stomach issues since June 2017. Every time I went to the bathroom, I would lose blood and I couldn’t eat anything. I became anemic and after my symptoms got even worse I finally went to the ER where I received a colonoscopy and was diagnosed with pancolitis. I was then in and out of the hospital a few times trying different name brand biologic medications that didn’t work. I felt like I had lost everything I loved. I couldn’t hike, rock climb or even play with my dog, Sally.
Finally, after I was in the hospital for a full week, I was switched to a biosimilar and within two days I started to feel normal. I went from paying for a biologic that didn’t work well to not paying anything for a biosimilar that truly helped. My last treatment was in early 2020 and since then I have been able to hike, rock climb and take my dog out for walks. If I had known about biosimilars earlier, I would have never tried anything else. Biosimilars truly gave me my life back!”
- [Infographic] Alternative to Biologic Medicines
- [Videos] AAM Patient Stories
- [Blog] Advocacy for Patient Access to Biosimilars
FDA-approved biosimilars have the potential to provide 1.2 million patients access to treatments for rheumatoid arthritis, Crohn’s disease, cancer and other chronic conditions, at a lower cost. Over the next ten years, biosimilars could save the entire U.S. health care system $54 billion. Find out more about how biosimilars truly benefit everyone in this infographic from AAM's Biosimilars Council.
Originally published on the Biosimilars Council website.
By Erica Klinger, Senior Director, Marketing